The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application notesIHC-Fo: Use at an assay dependent dilution.
WB: 1/200 - 1/1000. Predicted molecular weight: 86 kDa.
Not yet tested in other applications.
Optimal dilutions/concentrations should be determined by the end user.
FunctionMay play a role in a signaling pathway regulating nuclear functions of cell proliferation. Phosphorylates serine, threonine and tyrosine residues in its sequence and in exogenous substrates.
Tissue specificityUbiquitous. Highest levels in skeletal muscle, testis, fetal lung and fetal kidney.
Involvement in diseaseDefects in DYRK1A are the cause of mental retardation autosomal dominant type 7 (MRD7) [MIM:614104]. A disease characterized by primary microcephaly, severe mental retardation without speech, anxious autistic behavior, and dysmorphic features, including bitemporal narrowing, deep-set eyes, large simple ears, and a pointed nasal tip. Mental retardation is characterized by significantly below average general intellectual functioning associated with impairments in adaptative behavior and manifested during the developmental period.
Sequence similaritiesBelongs to the protein kinase superfamily. CMGC Ser/Thr protein kinase family. MNB/DYRK subfamily. Contains 1 protein kinase domain.
Developmental stageExpressed in the developing central nervous system. Overexpressed 1.5-fold in fetal Down syndrome brain.
DomainThe polyhistidine repeats act as targeting signals to nuclear speckles (PubMed:19266028).
Post-translational modificationsAutophosphorylated on tyrosine residues.